Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients

Aref, Salah; Azmy, Emad; El-Bakry, Kadry A.; Ibrahim, Lobna; Mabed, Mohamed

doi:10.1080/10245332.2017.1404276

Cited by 13 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, and consistent with data in MM and CLL, overexpression of CD200 was described in cases of both Hairy Cell leukemia (HCL), ALL and AML and correlated with prognosis for this disease [86,87]. Expression of CD200 at AML, both in secondary and at the diagnosis decreases activity of CD8 + T cell cytotoxic potential and the frequency of TNFα-, IL-2-and IFN-γ-producing CD4 + /CD8 + memory T cells, which contributes to the increased risk of relapse and worse overall survival and is independent predictor of cytogenetics [88][89][90].…”

Section: Cd200 Expression and Hematological Malignanciessupporting

confidence: 80%

CD200:CD200R Interactions and Their Importance in Immunoregulation

Kotwica-Mojzych

Jodłowska‐Jędrych

2021

IJMS

View full text Add to dashboard Cite

The molecule CD200, described many years ago as a naturally occurring immunomodulatory agent, capable of regulating inflammation and transplant rejection, has attracted additional interest over the past years with the realization that it may also serve as an important marker for progressive malignancy. A large body of evidence also supports the hypothesis that this molecule can contribute to immunoregulation of, among other diseases, infection, autoimmune disease and allergy. New data have also come to light to characterize the receptors for CD200 (CD200R) and their potential mechanism(s) of action at the biochemical level, as well as the description of a novel natural antagonist of CD200, lacking the NH2-terminal region of the full-length molecule. Significant controversies exist concerning the relative importance of CD200 as a ligand for all reported CD200Rs. Nevertheless, some progress has been made in the identification of the structural constraints determining the interaction between CD200 and CD200R, and this information has in turn proved of use in developing novel small molecule agonists/antagonists of the interaction. The review below highlights many of these newer findings, and attempts to place them in the broad context of our understanding of the role of CD200-CD200R interactions in a variety of human diseases.

show abstract

Section: Cd200 Expression and Hematological Malignanciessupporting

confidence: 80%

CD200:CD200R Interactions and Their Importance in Immunoregulation

Kotwica-Mojzych

Jodłowska‐Jędrych

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…In line with this, absence of the CD200/CD200R inhibitory axis results in enhanced anti-tumor responses (Kretz-Rommel et al, 2007;McWhirter et al, 2006;Petermann et al, 2007;Rygiel et al, 2012). Coherently, tumor CD200 expression in multiple human cancers is associated with poor prognosis (Aref et al, 2018;Chen et al, 2017;El Din Fouad et al, 2018;Moreaux et al, 2006) and blocking the CD200/CD200R inhibitory axis has been proposed as checkpoint blockade therapy in human cancer (Mahadevan et al, 2019).…”

Section: Introductionmentioning

confidence: 77%

Inhibitory CD200-receptor signaling is rewired by type I interferon

Vlist

Ramos

Hoogen

et al. 2020

Preprint

View full text Add to dashboard Cite

CD200 Receptor 1 (CD200R) is an established inhibitory immune receptor that inhibits TLRinduced cytokine production through Dok2 and RasGAP. RasGAP can be cleaved under certain conditions of mild cellular stress. We found that in the presence of cleaved RasGAP, CD200R loses its capacity to inhibit rpS6 phosphorylation. Furthermore, IFNα prestimulation of human mononuclear cells results in increased amounts of cleaved RasGAP.Coherently, upon pretreatment with increasing concentrations of IFNα, CD200R gradually shifts from an inhibitor to a potentiator of TLR7/8-induced IFNG mRNA production. In peripheral blood mononuclear cells from Systemic Lupus Erythematosus (SLE) patients, a prototypic type I IFN disease, we found an increased proportion of cleaved RasGAP compared to healthy controls. In line with this, in subsets of SLE patients the inhibitory function of CD200R is lost or converted to a potentiating signal for IFNG mRNA production.Thus, our data show that type I IFN rewires CD200R signaling and suggest that this cellextrinsic regulation of signaling could contribute to perpetuation of inflammation in SLE.

show abstract

“…Recently, antibody-based anticancer treatment was analyzed with the expression levels of NCAM1. The phase 1/2 study is ongoing, since NCAM1 is expressed on several malignancies, including SCLC [58][59][60], or could be available to predict prognosis in adult acute lymphoblastic leukemia patient [61]. RET was identified in 1985.…”

Section: Discussionmentioning

confidence: 99%

Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer

et al. 2020

View full text Add to dashboard Cite

Lung cancer is one of the leading causes of death worldwide. Therefore, understanding the factors linked to patient survival is essential. Recently, multi-omics analysis has emerged, allowing for patient groups to be classified according to prognosis and at a more individual level, to support the use of precision medicine. Here, we combined RNA expression and miRNA expression with clinical information, to conduct a multi-omics analysis, using publicly available datasets (the cancer genome atlas (TCGA) focusing on lung adenocarcinoma (LUAD)). We were able to successfully subclass patients according to survival. The classifiers we developed, using inferred labels obtained from patient subtypes showed that a support vector machine (SVM), gave the best classification results, with an accuracy of 0.82 with the test dataset. Using these subtypes, we ranked genes based on RNA expression levels. The top 25 genes were investigated, to elucidate the mechanisms that underlie patient prognosis. Bioinformatics analyses showed that the expression levels of six out of 25 genes (ERO1B, DPY19L1, NCAM1, RET, MARCH1, and SLC7A8) were associated with LUAD patient survival (p < 0.05), and pathway analyses indicated that major cancer signaling was altered in the subtypes.

show abstract

Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients

Abstract: CD200 and/or CD56 positive expression in B-ALL patients at diagnosis is a poor prognostic biomarker. Identification of CD200 and CD56 expression at diagnosis is recommended for a better stratification of adult B-ALL patients.

Cited by 13 publications

References 46 publications

CD200:CD200R Interactions and Their Importance in Immunoregulation

CD200:CD200R Interactions and Their Importance in Immunoregulation

Inhibitory CD200-receptor signaling is rewired by type I interferon

Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer

Contact Info

Product

Resources

About